Compounded and Counterfeit Semaglutide: What the FDA Is Warning About
Shortages pushed patients toward compounded semaglutide. The FDA's latest alert shows why that workaround carries real risk.
Aug 5, 2024

Search
20 stories for“semaglutide”
Shortages pushed patients toward compounded semaglutide. The FDA's latest alert shows why that workaround carries real risk.
Aug 5, 2024

Novo Nordisk folded Rybelsus into the Ozempic name in May and put a self-pay price on it. Getting a peptide to survive the stomach is a real achievement, but the tablet is not simply the injection in another form.
Aug 11, 2026

Semaglutide now has a heart disease approval too. Here is what the STEP and SELECT trial data really says, and what it does not.
Mar 13, 2024

Ozempic, Mounjaro and the drug that has not arrived yet are not three versions of the same thing. They hit different receptors, produce different results, and suit different people.
Aug 11, 2026

Tirzepatide just beat semaglutide head to head in a major trial. Here is what SURMOUNT and SURPASS data actually shows about hitting two receptors.
Dec 9, 2024

New body composition data compares lean mass loss on tirzepatide and semaglutide. Here is what is measured, and what remains unclear.
Jun 15, 2026

Tirzepatide just earned an approval that has nothing to do with the scale. Here is what SELECT, FLOW and the new sleep apnea data show.
Jan 8, 2025

Trial data on stopping semaglutide shows most of the lost weight comes back within a year. Here is what the STEP 1 extension found.
May 15, 2024

Semaglutide and tirzepatide went from diabetes treatment to celebrity shortcut to a genuine health story. What happens when one drug becomes a cultural moment.
Apr 20, 2024

A Yale study found semaglutide switches the brain's hunger neurons on rather than off, and that those neurons are required for fat loss to last. Remove them and the mice ate just as little and regained the weight within fifteen days.
Aug 25, 2026

GLP-1 receptor agonists did not start as weight loss drugs. Here is the biology behind Ozempic, Mounjaro and the hormone they mimic.
Jan 25, 2024

Berberine lowers cholesterol and blood sugar in small trials, but comparing it to semaglutide misreads both the data and the biology.
Feb 14, 2024

Insulin is a peptide. So is Ozempic. So is the unlabelled vial someone is selling on Telegram. The word describes a chemical class, not a level of evidence, and that gap is where the market lives.
Aug 11, 2026

Retatrutide just posted phase 3 weight loss data hitting three hormone receptors at once. Here is what is confirmed and what remains unproven.
May 27, 2026

Semaglutide hits one receptor and tirzepatide hits two. The third one retatrutide adds is glucagon, which does the opposite of what a diabetes drug is supposed to do. It is also where the liver results and the safety questions both come from.
Aug 20, 2026

TRIUMPH-2 and TRIUMPH-3 read out in July, following TRIUMPH-1 in May. Across the programme the triple agonist has produced weight loss in a range no approved obesity drug has reached, with a filing due in early 2027.
Aug 11, 2026

Nausea is the least of it. Here is an honest look at GLP-1 side effects, the thyroid warning, pancreatitis and who is advised to avoid them.
Jul 10, 2024

Research use only is a legal phrase, not a quality standard. Testing of peptides bought online keeps finding the wrong dose, the wrong compound, or contamination in something people inject at home.
Aug 12, 2026

On 23 and 24 July, an FDA advisory committee looked at seven peptides and recommended that pharmacies be allowed to compound several of them. The vote is not binding, and the evidence gap has not moved.
Aug 11, 2026

Peptide is a chemical category, not a claim. The two versions most people actually buy are the ones with the least regulation and, oddly, the best safety record. Here is what the trials support and what physics gets in the way of.
Aug 20, 2026
